Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.33 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.33 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333627 | 0.97 | TSHR (0.41) | TSHRHPGDTHRBTHRASMPD1 | |
| SCHEMBL7775382 | 0.89 | TSHR (0.37) | TSHRHPGDTHRBTHRA | |
| SCHEMBL60550 | 0.89 | TSHR (0.52) | TSHRSMPD1FAAHZDHHC20ZDHHC2 | |
| SCHEMBL160397 | 0.89 | TSHR (0.50) | TSHRHPGDTHRBTHRASMPD1 | |
| SCHEMBL6986547 | 0.87 | TSHR (0.55) | TSHRSMPD1FAAHLMNAZDHHC20 | |
| SCHEMBL22572596 | 0.87 | TSHR (0.55) | TSHRSMPD1FAAHLMNAZDHHC20 | |
| SCHEMBL4578058 | 0.87 | TSHR (0.48) | TSHRHPGDTHRBTHRASMPD1 | |
| SCHEMBL22572612 | 0.87 | TSHR (0.55) | TSHRSMPD1FAAHLMNAZDHHC20 | |
| SCHEMBL22572582 | 0.87 | TSHR (0.55) | TSHRSMPD1FAAHLMNAZDHHC20 | |
| SCHEMBL487209 | 0.87 | TSHR (0.55) | TSHRSMPD1FAAHLMNAZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728339-A1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | Merck Patent GmbH (DE) | 2020-10-28 | — | — | EP | claimed |
| US-20150259500-A1 | PREPARATION OF FOAM MATERIALS DERIVED FROM RENEWABLE RESOURCES | PROCTER & GAMBLE (US) | 2015-09-17 | — | — | US | claimed |
| EP-2632977-A1 | PREPARATION OF FOAM MATERIALS DERIVED FROM RENEWABLE RESOURCES | The Procter and Gamble Company (US) | 2013-09-04 | — | — | EP | claimed |
| US-20120108692-A1 | PREPARATION OF FOAM MATERIALS DERIVED FROM RENEWABLE RESOURCES | THE PROCTER & GAMBLE COMPANY | 2012-05-03 | — | — | US | claimed |
| WO-2012058081-A1 | PREPARATION OF FOAM MATERIALS DERIVED FROM RENEWABLE RESOURCES | THE PROCTER & GAMBLE COMPANY (US) | 2012-05-03 | — | — | WO | claimed |
| US-20020128338-A1 | Foam materials and high internal phase emulsions made using oxidatively stable emulsifiers | PROCTER & GAMBLE COMPANY, THE | 2002-09-12 | — | — | US | claimed |
| US-6444716-B1 | EMULSIFIER IS PARTIALLY DEHYDRATED REACTION PRODUCT OF: A HYDROCARBYL SUBSTITUTED SUCCINIC ACID OR ANHYDRIDE, AND A POLYAMINE, HYDROXYAMINE OR MIXTURES | THE PROCTER & GAMBLE COMPANY | 2002-09-03 | — | — | US | claimed |
| US-6365642-B1 | FORMING A WATER-IN-OIL EMULSION FROM OIL PHASE COMPRISING ALKLY (METH)ACRYLATE MONOMER, CROSSLINKER, EMULSIFIER AND WATER PHASE COMPRISING AQUEOUS SOLUTION CONTAINING ELECTROLYTE; CURING TO FORM FOAM MATERIAL | THE PROCTER & GAMBLE COMPANY | 2002-04-02 | — | — | US | claimed |
| WO-2026107411-A1 | PACKAGED FEMININE HYGIENE PAD PRODUCT ADAPTED FOR DISCREET CARRY AND ACCESS, AND MANUFACTURING PROCESS | THE PROCTER & GAMBLE COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026106828-A1 | PACKAGED FEMININE HYGIENE PAD PRODUCT ADAPTED FOR DISCREET CARRY AND ACCESS, AND MANUFACTURING PROCESS | THE PROCTER & GAMBLE COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260137565-A1 | PACKAGED FEMININE HYGIENE PAD PRODUCT ADAPTED FOR DISCREET CARRY AND ACCESS, AND MANUFACTURING PROCESS | THE PROCTER & GAMBLE CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260138767-A1 | PACKAGED FEMININE HYGIENE PAD PRODUCT ADAPTED FOR DISCREET CARRY AND ACCESS, AND MANUFACTURING PROCESS | THE PROCTER & GAMBLE CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260102535-A1 | ABSORBENT ARTICLES INCLUDING HIPE FOAM IMPARTED WITH COLOR, AND METHOD OF MANUFACTURE | PROCTER & GAMBLE (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4712924-A1 | FEMININE HYGIENE PAD WITH FOAM ABSORBENT LAYER COMPONENT AND IMPROVED BODY CONFORMITY | The Procter & Gamble Company (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20110159206-A1 | PROCESS FOR THE PRODUCTION OF HIGH INTERNAL PHASE EMULSION FOAMS | MERRIGAN STEVEN RAY | 2011-06-30 | — | — | US | disclosed |
| US-20110160326-A1 | HIGH INTERNAL PHASE EMULSION FOAM HAVING LOW LEVELS OF UNPOLYMERIZED MONOMERS | THE PROCTER & GAMBLE COMPANY | 2011-06-30 | — | — | US | disclosed |
| EP-1325064-B1 | PREPARATION OF FOAM MATERIALS FROM HIGH INTERNAL PHASE EMULSION | PROCTER & GAMBLE (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1325064-A2 | PREPARATION OF FOAM MATERIALS FROM HIGH INTERNAL PHASE EMULSION | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002031031-A2 | PREPARATION OF FOAM MATERIALS FROM HIGH INTERNAL PHASE EMULSION | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-18 | — | — | WO | disclosed |
| US-6365642-B1 | FORMING A WATER-IN-OIL EMULSION FROM OIL PHASE COMPRISING ALKLY (METH)ACRYLATE MONOMER, CROSSLINKER, EMULSIFIER AND WATER PHASE COMPRISING AQUEOUS SOLUTION CONTAINING ELECTROLYTE; CURING TO FORM FOAM MATERIAL | THE PROCTER & GAMBLE COMPANY | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137565-A1 | PACKAGED FEMININE HYGIENE PAD PRODUCT ADAPTED FOR DISCREET CARRY AND ACCESS, AND MANUFACTURING PROCESS | SHBG, SMCHD1, CUTA | TSHR 2636/4885HPGD 2628/4885THRB 3458/4885 |
| US-20260138767-A1 | PACKAGED FEMININE HYGIENE PAD PRODUCT ADAPTED FOR DISCREET CARRY AND ACCESS, AND MANUFACTURING PROCESS | CUTA, SMCHD1, RFT1 | TSHR 3932/4885HPGD 1840/4885THRB 4218/4885 |
| US-20260102535-A1 | ABSORBENT ARTICLES INCLUDING HIPE FOAM IMPARTED WITH COLOR, AND METHOD OF MANUFACTURE | FANCF, RAD51, CD44 | TSHR 2655/4885HPGD 732/4885THRB 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.